MK-0249

DB11910InvestigationalSmall molecule

MK0249 has been used in trials studying the treatment of Hypopnea Syndrome, Alzheimer's Disease, Paranoid Schizophrenia, Sleep Apnea, Obstructive, and Excessive Daytime Sleepiness, among others.

Mechanism: Pharmacologically active on Histamine H3 receptor
Curator reviewed
Formula / weight: C₂₃H₂₄F₃N₃O₂ · 431.459 g/mol (avg)
Code names: MK0249

Resolves to

Compound

UNIIKF50235Q04CAS1167574-41-5ChEMBLCHEMBL476323PubChem11697697

Structure

InChIKeyDDDZBLNULGDPGA-UHFFFAOYSA-NSMILESCC1=NC2=CC=CC(=C2C(=O)N1C1=CC=C(OCCCN2CCCC2)C=C1)C(F)(F)F

Targets

Q9Y5N1HRH3

What you can answer from here — as of June 15, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

5Clinical trialsPhase, status and sponsor resolved per trial

6+ReferencesStructured and connected to the statements they support

Which drugs share a target with MK-0249, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account